- ISIN: CH0106213793
- Land: Schweiz
Nachricht vom 06.04.2021 | 19:00
Polyphor Annual General Meeting 2021
Polyphor AG / Key word(s): AGMEGM
Allschwil, Switzerland, April 6, 2021
Polyphor Annual General Meeting 2021
Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the 24th Annual General Meeting (AGM) with a significant majority, with the exception of the proposed increase of the conditional capital for the employee stock option plan (ESOP), which did not receive the required two thirds majority. In line with the COVID-19 Ordinance 2 of the Swiss Federal Council, no shareholders were allowed to attend the AGM in person. The independent proxy represented 47.7 percent of the company's shares.
The members of the Board of Directors, Kuno Sommer, Bernard Bollag, Silvio Inderbitzin and Andreas Wallnöfer, were re-elected for a further year in office and Hugh O'Dowd was elected as a new member of the Board. In addition, shareholders confirmed Kuno Sommer as Chairman of the Board of Directors. The agenda items on compensation for the members of the Board of Directors and the executive management were also approved. Furthermore, the reduction of the company's share capital through decrease of nominal value of shares was approved. The management report, the consolidated financial statements, and the annual financial statements for 2020 were also approved.
"On behalf of the Board of Directors, I would like to thank all of Polyphor's shareholders for their trust and support at today's AGM," said Kuno Sommer, Chairman of the Board of Directors.
The invitation with proposals and explanations on the agenda items is available on the company's website at www.polyphor.com/investor-relations/corporate-governance.
For further information please contact:
+41 44 447 12 21
Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of ad hoc announcement
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1181502|
|End of Announcement||EQS Group News Service|
Event im Fokus
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
11 Perlen im „GBC Fonds Champions 2021“
Im Rahmen der aktuellen Studie „GBC Fonds Champions 2021“ haben wir elf versteckte Fondsperlen mit dem Kriterium einer Mindestbewertung von 4 von 5 GBC-Falken ausgewählt. Auch tragen wir dem gesteigerten Investoreninteresse nach nachhaltigen Investments Rechnung und haben drei nachhaltige Fonds ausgewählt. Übrigens, die Fonds aus unserer letzten Ausgabe haben im Schnitt eine Performance von plus 31,8 % erreicht.
Der AKTIONÄR News
17. April 12:01 CD Projekt: Rekord-Jahr – nächster Kurs-Einbruch
17. April 08:04 Nike, Hype und Riesengewinne
17. April 06:00 Nel und ITM Power: Jetzt meldet sich Morgan Stanley zu Wort
16. April 18:55 Coinbase: Diese Kursziele sind der Hammer
News im Fokus
Vonovia SE: Aktionäre beschließen auf Hauptversammlung Dividende von 1,69 Euro (News mit Zusatzmaterial)
16. April 2021, 16:41
Conference Call 11.05.2021 (Webcast)
11. Mai 2021
Original-Research: Mountain Alliance AG (von Montega AG): Kaufen
16. April 2021